• Intellia Therapeutics will present seven lonvoguran ziclumeran (lonvo-z) studies in hereditary angioedema at ACAAI’s November 12-16, 2026, meeting.
• Planned presentations report consistent benefit across Phase 3 HAELO patient subgroups and improved quality of life following one-time treatment.
• Oral presentations on November 14 will cover four-year durability and safety, alongside freedom from attacks and long-term preventive treatment.
• A November 12 investor webcast will review clinical data and preparations for a planned commercial launch of lonvo-z in hereditary angioedema.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290800PRIMZONEFULLFEED9855359) on October 29, 2026, and is solely responsible for the information contained therein.